Order For OTC Emergency Contraceptive Access Exceeds Court’s Authority – DoJ
This article was originally published in The Tan Sheet
A judge on May 7 will consider DoJ’s argument to stay an order that FDA allow OTC sales of all nonprescription emergency contraceptives. DoJ is appealing the order, and argues that without a stay, FDA’s authority would be undermined and Teva would unfairly lose additional market exclusivity for Plan B One-Step.
You may also be interested in...
HHS Secretary Sebelius says Teva must show more evidence of how young adolescent females would use Plan B One-Step as an OTC. But obtaining such clinical data for the emergency contraceptive – in excess of what FDA already needed to approve it – appears nearly impossible, experts say.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”